Nat. Rev. Cardiol. doi: /nrcardio

Slides:

Advertisements

Similar presentations

The Late Sodium Current in the cardiac myocite: How viable as a new therapeutic target in angina? SPONSORED SATELLITE SESSION Dr Stephen Holmberg Lead.

Advertisements

How do we further reduce angina in patients already treated with a hemodynamic agent? Benefits of adding a metabolic agent to other antianginal drugs (

European guidelines on the management of stable coronary artery disease Key points & new position for Ivabradine and Trimetazidine ESC 2013 Montalescot.

Benefits of adding a energetic agent to  -blockers to achieve optimal reduction of angina. Review of the main studies.

Antianginal Drugs Learning outcomes Recognize variables contributing to a balanced myocardial supply versus demand Expand on the drugs used to alleviate.

Clinical Management of Chronic Stable Angina. Anti-ischemic strategies in stable CAD Medical therapyPCICABG Initial therapy Recurrent ischemia TMREECPSCS.

Algorithm for the treatment of atrial fibrillation (AF) and atrial flutter. (BB, β-blocker; CCB, calcium channel blocker [i.e., verapamil or diltiazem];

Nat. Rev. Cardiol. doi: /nrcardio

Formative Test.

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Lung and pleural ultrasonography

Figure 2 Different manifestations of myocardial ischaemia

Creatinine clearance (mL/min) n All-cause mortality (%)

Figure 5 BMI and cardiorespiratory fitness levels

Figure 4 BMI and mortality in patients with heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Energy supply–demand matching in health and heart failure

Figure 1 Mechanisms of metastatic growth in the heart

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Global rates of sodium, fruit, and vegetable intake

Figure 2 Size categorization of airborne pollutants

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Three-year survival rates on the basis of body composition

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 Prevalence of HFpEF and HFrEF by age

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Cardiovascular risk and disease across the life-course

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Decision tree integrating the assessment,

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Neural crest cell migration

Figure 2 Global cost of HF per capita in 2012

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Milestones in coronary angioplasty

Figure 3 Challenges for big data applications in cardiovascular care

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Effects of cardiovascular medication on the fetus

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 5 Bioresorbable vascular scaffold apposition and strut coverage

Figure 6 Cardiac fibroma

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 12 Cardiac gossypiboma

Figure 6 The neurogenic components of angina

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 Electrocardiogram patterns associated with Brugada syndrome

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Impaired mitochondrial capacity and function in heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Kaplan-Meier Curves for the Percentages of Subjects with Microalbuminuria during Treatment with Trandolapril plus Verapamil or Placebo Piero Ruggenenti.

Antianginal Drugs Learning outcomes

Fig. 3: Possible algorithm for controlling blood pressure in diabetic patients with microalbuminuria. [This algorithm is based on the opinions and practice.

Presentation transcript:

Nat. Rev. Cardiol. doi:10.1038/nrcardio.2017.131 Figure 4 Possible combinations of classes of antianginal drugs according to different comorbidities Figure 4 | Possible combinations of classes of antianginal drugs according to different comorbidities. BB, β-blockers; DHP, dihydropyridine calcium-channel blockers; DILT, diltiazem; HR, heart rate; IVAB, ivabradine; NIC, nicorandil; NITR, nitrates; RAN, ranolazine; TRIM, trimetazidine; VER, verapamil. Ferrari, R. et al. (2017) A ‘diamond’ approach to personalized treatment of angina Nat. Rev. Cardiol. doi:10.1038/nrcardio.2017.131